Illinois News Desk

Delveinsight Business Research LLP

DelveInsight’s “Diabetic Macular Edema Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Diabetic Macular Edema market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Diabetic Macular Edema drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Diabetic Macular Edema treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Diabetic Macular Edema: An Overview

Diabetic Macular Edema (DME) is triggered by diabetic retinopathy (DR), a well-known complication of diabetes. DR is the most prevalent diabetic eye disease and the leading cause of irreversible blindness in people in their working years in developed and other developing countries. Common signs and symptoms include dark spots like a smudge on glasses or gaps that may appear in the vision, blurred vision, double vision, colors can fade, or the affected person may find bright light or glare difficult.

All people with Type 1 or Type 2 diabetes are at risk for DR and DME. The risk of developing DR or DME increases significantly the longer a person has diabetes. The American Academy of Ophthalmology (AAO) estimates that nearly 80% of patients with Type 1 diabetes will have developed DR after living with diabetes for 15 years. There is a 50% chance that patients with Type 2 diabetes will develop DR after living with diabetes for around 20 years.

Diabetic Macular Edema diagnosis is clinically performed by fundoscopy; when the center of the macula (fovea centralis) is thickened or swollen, this is referred to as clinically significant central-involved macular edema (CI-CSME). It is referred to as a clinically significant non-central-involved macular edema (NCI-CSME) when it is unaffected.

Diabetic Macular Edema Market Key Facts

• In 2020, the overall prevalent cases of Diabetic Macular Edema were accessed to be around 1,862,000+ in the 7MM.

• In the United States, the total number of prevalent cases of Diabetic Macular Edema was 1,026,000+ in 2020.

• In 2020, the total prevalent cases of Diabetic Macular Edema were 641,000+ in EU-5.

• In Japan, the total number of prevalent cases of Diabetic Macular Edema was 194,000+ in 2020.

• Diabetic Macular Edema affects more males as compared to females and is more prevalent in the elderly population. 

• In 2020, 193,979 non-central-involved cases of Diabetic Macular Edema and 267,876 central-involved Diabetic Macular Edema cases were observed in the United States.

• Diabetic Macular Edema Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Diabetic Macular Edema and the launch of new therapies in the market. 

Diabetic Macular Edema Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Diabetic Macular Edema pipeline therapies. It also thoroughly assesses the Diabetic Macular Edema market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Diabetic Macular Edema drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Diabetic Macular Edema Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Diabetic Macular Edema epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Diabetic Macular Edema epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Diabetic Macular Edema Epidemiology, Segmented as –

• Total Prevalent Cases of Diabetic Macular Edema in the 7MM [2019–2032]

• Gender-specific Diagnosed Cases of Diabetic Macular Edema in the 7MM [2019–2032]

• Total Diagnosed Cases of Diabetic Macular Edema in the 7MM [2019–2032] 

• Age-Specific Diagnosed Cases of Diabetic Macular Edema in the 7MM [2019–2032]

• Treated cases of Diabetic Macular Edema in the 7MM [2019–2032]

• Subgroup-specific Diagnosed Cases of Diabetic Macular Edema in the 7MM [2019–2032]

Diabetic Macular Edema Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Diabetic Macular Edema market or expected to be launched during the study period. The analysis covers the Diabetic Macular Edema market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Diabetic Macular Edema drugs based on their sale and market share.

The report also covers the Diabetic Macular Edema pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Diabetic Macular Edema companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Diabetic Macular Edema Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-market

Diabetic Macular Edema Therapeutics Analysis

Diabetic Macular Edema treatment mainly involves the usage of anti-VEGF Drugs, corticosteroids, and Laser photocoagulation. The current standard of care for DME is intravitreal injection. Nonsteroidal anti-inflammatory drugs (NSAIDs), in the form of eye drops, are sometimes used either before or after cataract surgery to prevent the development of macular edema. 

Currently, intravitreal anti-VEGF agents are the preferred first-line Diabetic Macular Edema treatment. The three most used anti-VEGF drugs are Avastin (off-label), Eylea, and Lucentis. Corticosteroids are mostly a second-line treatment option. These anti-inflammatory drugs are usually administered via eye drops, pills, or injections of sustained-release corticosteroids into or around the eye. The US FDA-approved sustained-release corticosteroid implants for more serious or longer-lasting conditions are Ozurdex and Iluvien.

Several major pharma and biotech companies are developing therapies for Diabetic macular edema. Currently, Mylan Pharmaceuticals is leading the therapeutics market with its Diabetic macular edema drug candidates in the most advanced stage of clinical development.

Diabetic Macular Edema Companies Actively Working in the Therapeutics Market Include

Adverum Biotechnologies, Allergan (AbbVie), Allegro Ophthalmics, Allgenesis Biotherapeutics, Ascentage Pharma, AsclepiX Therapeutics, Bausch Health, Celltrion, Clearside Biomedical, Exonate, Graybug Vision, KalVista Pharmaceuticals, Kodiak Sciences, MingSight Pharmaceuticals, Molecular Partners, Mylan Pharmaceuticals, Novartis, Ocuphire Pharma, Opthea, Oxurion, Rezolute, Roche, YD Life Science, and many others.

Emerging and Marketed Diabetic Macular Edema Therapies Covered in the Report Include:

• MYL-1701P: Mylan Pharmaceuticals

• KSI-301: Kodiak Sciences

• CT-P42: Celltrion

• Faricimab (RG 7716): Roche

• Beovu (RTH258; brolucizumab): Novartis

• ADVM-022: Adverum Biotechnologies

• THR-149: Oxurion

• LKA651: Novartis

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Diabetic Macular Edema Competitive Intelligence Analysis

4. Diabetic Macular Edema Market Overview at a Glance

5. Diabetic Macular Edema Disease Background and Overview

6. Diabetic Macular Edema Patient Journey

7. Diabetic Macular Edema Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Diabetic Macular Edema Treatment Algorithm, Current Treatment, and Medical Practices

9. Diabetic Macular Edema Unmet Needs

10. Key Endpoints of Diabetic Macular Edema Treatment

11. Diabetic Macular Edema Marketed Therapies

12. Diabetic Macular Edema Emerging Drugs and Latest Therapeutic Advances

13. Diabetic Macular Edema Seven Major Market Analysis

14. Attribute Analysis

15. Diabetic Macular Edema Market Outlook (In US, EU5, and Japan)

16. Diabetic Macular Edema Companies Active in the Market

17. Diabetic Macular Edema Access and Reimbursement Overview

18. KOL Views on the Diabetic Macular Edema Market

19. Diabetic Macular Edema Market Drivers

20. Diabetic Macular Edema Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Cartilage Diseases Market

“Cartilage Diseases Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cartilage Diseases market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Cartilage Diseases market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research